Ionis Pharmaceuticals (IONS) Amortization of Deferred Charges (2013 - 2026)

Ionis Pharmaceuticals' Amortization of Deferred Charges history runs 14 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 34.71% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $11.1 million, a 9.67% increase from a year earlier, with the FY2025 full-year figure at $10.2 million, up 2.06% from the prior year.
• Amortization of Deferred Charges climbed to $3.5 million in Q1 2026 per IONS's latest filing, from $3.4 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $5.0 million in Q4 2024 and bottomed at -$43000.0 in Q2 2022.
• The 5-year median for Amortization of Deferred Charges is $1.7 million (2023), against an average of $2.3 million.
• Across the five-year window, Amortization of Deferred Charges sank 102.39% in 2022 and soared 3541.86% in 2023, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $1.3 million in 2022, then jumped by 272.27% to $5.0 million in 2023, then grew by 0.86% to $5.0 million in 2024, then tumbled by 31.45% to $3.4 million in 2025, then rose by 1.19% to $3.5 million in 2026.
• Per Business Quant, the three latest IONS Amortization of Deferred Charges figures stand at $3.5 million (Q1 2026), $3.4 million (Q4 2025), and $3.5 million (Q3 2025).